4.3 Letter

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia

Journal

MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 44, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2020.102315

Keywords

Ocrelizumab; Multiple Sclerosis; SARS-CoV-2; COVID-19; Immunuglobulins

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available